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ABSTRACT
Growing interest in extracellular vesicles (EVs, including exosomes and microvesicles) as therapeu-
tic entities, particularly in stem cell-related approaches, has underlined the need for standardiza-
tion and coordination of development efforts. Members of the International Society for
Extracellular Vesicles and the Society for Clinical Research and Translation of Extracellular Vesicles
Singapore convened a Workshop on this topic to discuss the opportunities and challenges associ-
ated with development of EV-based therapeutics at the preclinical and clinical levels. This review
outlines topic-speciﬁc action items that, if addressed, will enhance the development of best-
practice models for EV therapies. STEM CELLS TRANSLATIONAL MEDICINE 2017;00:00–000
SIGNIFICANCE STATEMENT
Extracellular vesicles (EVs) have been implicated as important and sometimes sufficient media-
tors of the effects of stem cells. Best-practice models must be developed for the rapid develop-
ment of exosomes, microvesicles, and other EVs as therapeutic entities.
INTRODUCTION
Extracellular vesicles (EVs) are membrane bound
entities that transmit signals between cells via all
major classes of biomolecules [1–3]. The term
“EV” encompasses microvesicles, exosomes,
oncosomes, and other vesicles [4, 5] that may be
variously deﬁned by origin, size, and markers [3,
4]. EVs interact with target cells by binding to cell
surface receptors, transfer of membrane proteins
(e.g., signaling receptors), membrane fusion,
endosomal uptake, and cargo extrusion through
vesicle-cell channels [1, 6–8]. The EV protein and
RNA compositions generally reﬂect that of pro-
genitor cells. Some proteins, such as CD9, CD63,
CD81, and MHCII, are expressed on many EVs [8],
while others may deﬁne subtypes [9]. EV
membrane proteins may target EVs to speciﬁc
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STANDARDS, POLICIES, PROTOCOLS, AND REGULATIONS
FOR CELL-BASED THERAPIES
cells [1, 10]. Found in every bodily ﬂuid examined, EVs may con-
tain cellular markers from difﬁcult-to-access anatomical sites, mak-
ing them strong candidates as biomarkers of disease [11]. Their
ability to transport molecules and to target speciﬁc cell popula-
tions raise possibilities for their development as therapeutics.
EVs, particularly those derived from mesenchymal stem/stro-
mal cells (MSCs), have been shown to have intrinsic therapeutic
properties for applications as diverse as wound healing, inﬂamma-
tion, hypertension, cardiovascular disease, brain injury, and can-
cers [4, 12, 13]. EVs also exert immunomodulatory pressures
depending on progenitor cell and application [8, 14]. The immu-
nostimulatory properties of EVs have led to development of EV
vaccine platforms against both infectious agents and tumors [4],
while the immunosuppressive property of certain EVs could allevi-
ate immune diseases such as graft-versus-host disease (GVHD)
[15]. These therapeutic potentials position EVs as highly competi-
tive alternatives to stem cells, including stem cells such as MSCs
that have proven to be safe in many clinical trials and therapeuti-
cally efﬁcacious in several disease indications. EVs are likely to be
as safe as or safer than their parental secreting stem cells,
although half-life (of the EVs or of the therapeutic effect) may not
be as long. Also, the manufacture, storage, transport and end-use
of nonviable stem cell EV therapeutics, as opposed to viable stem
cell therapeutics, are less complex. Together, these factors have
helped expedite the prospect of translating stem cell EVs into clini-
cal applications. In anticipation of these continuing, challenging
developments, the International Society for Extracellular Vesicles
(ISEV) and the Society for Clinical Research and Translation of
Extracellular Vesicles Singapore (SOCRATES) convened a Workshop
to discuss the most recent advances in EV technology and clinical
testing and to develop long-term perspectives for creating best-
practice models for the therapeutic use of EVs. Here, we share our
conclusions and action items to spur the development, testing,
and approval of EV-based therapeutics.
EV PRODUCTION AND ISOLATION
Best practices for sample collection and analysis of EVs have been
treated in position papers and statements from ISEV [16–19] and
a variety of other publications [20–26]. These publications should
be consulted for the most complete guidance on isolation and
characterization. Here, we summarize these topics in the context
of moving toward clinical testing of EV-based therapeutics.
Methods of EV Production
EV production on an industrial scale must eventually occur in
deﬁned or otherwise serum-free conditions, and the cellular
source must be considered carefully. Ideally, similar to the case for
cellular therapeutics, xenogenic components would be avoided
during the production process. Current strategies are to use either
chemically deﬁned media or human platelet lysate (HPL) as a
serum replacement. Chemically deﬁned media may not rely on
limiting raw materials and allow more control of production con-
ditions, crucial for industrial-scale manufacture. However, contro-
versy remains as to when the switch to deﬁned media must occur
in the progression from basic research to clinical application. Since
removing serum may change the phenotype and function of cells
and the EVs they produce [27, 28], a culture change would neces-
sitate conﬁrmation that EV properties remain the same across
media. HPL is already used for the production of functionally
efﬁcient cellular therapeutics [29–31]. Due to interindividual dif-
ferences in the composition of given HPL preparations, conven-
tionally, platelet units from tens of blood donors are pooled to
limit batch-to-batch variations [32]; even larger pools may be
used. Since each given batch has to be qualiﬁed for the intended
use, larger batch sizes are cheaper to produce than multiple
smaller ones. However, considering that pooled HPL may contain
unidentiﬁed pathogenic components that theoretically might be
spread with the product, discussions are ongoing to limit allowed
batch sizes. Independent of the batch size, there is limited supply
of raw material for HPL due to a naturally restricted number of
blood donations worldwide, which may hamper global up-scaling
strategies.
Producer cells must be chosen considering the intended use,
as EVs may reﬂect molecular expression patterns and function(s)
of the producer cell. If EVs are to be used as a drug delivery sys-
tem [33], the method of engineering and loading cargo must be
considered. For example, post-production nucleic acid loading of
EVs by electroporation has been reported by some to have low
efﬁciency (0.05%), with nucleic acid aggregates often mistaken for
loaded EVs [34]. Conversely, synthetic lipid nanoparticles (LNPs)
have high nucleic acid encapsulation efﬁciency (>80%) [35]. Fus-
ing these LNPs with EVs in a low pH environment creates a
“hybridosome” replete with cargo and, if functionalized with spe-
ciﬁc membrane proteins, capable of cell targeting and improved
biodistribution. However, the possibility that some desirable fea-
tures of EVs are not transferred to hybridosomes, but are lost
upon fusion, requires further investigation.
Isolation and Purification of EVs
Isolation and puriﬁcation of EVs are linked concepts. Isolation
methods are techniques used to separate vesicles from non-
vesicular components. In principle, a pure EV product would con-
tain no non-vesicular components. However, there is presently no
accepted measurement for a pure EV product. Degree of purity, in
contrast, is a normalization metric to assess and compare product
composition and function across batches or studies. Ratio of pro-
tein to particle count is one possible purity metric [36]. Sai Kiang
Lim proposes a metric based on amount of EV-speciﬁc biomarker
per unit weight protein. Such assessment, however limited to EVs
from a particular cell source, could facilitate comparison of EV
purity among laboratories using similar cells. Certainly, a purity
metric could help map therapeutic properties of EVs to speciﬁc EV
components for elucidation of molecular mechanism of action
(MoA). A truly pure EV preparation, although, may not be as use-
ful as an EV preparation with a lesser, deﬁned degree of purity.
While puriﬁcation could result in concentration of the therapeutic
effector(s), it is also possible that stringent, harsh puriﬁcation pro-
cedures required to obtain a pure product could result in loss of
function, through damage to EV-intrinsic effectors or even to loss
of extrinsic, loosely associated factors that act with EVs to exert
function. Indeed, as important as purity will continue to be for
molecular studies, potency, reproducibility, and stability measures
may be at least as important in therapeutics development.
The optimal EV isolation method depends on the intended
therapeutic use, route of administration, starting material (e.g.,
milk, plasma, urine, cell culture), and desired end product (e.g.,
CD631 or total EVs). Several leading technologies are described in
Table 1; guidance was also provided by Lener, et al [4]. Highest
purity of EV subsets is thought to be achieved by ﬂotation and
density gradient centrifugation. However, purity is often achieved
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at the expense of scalability, yield, cost, and therapeutic potency.
In recent years, numerous commercial EV isolation kits (e.g., [37])
have appeared, most of them based on precipitation using poly-
mers such as polyethylene glycol. (This approach can of course be
used without a kit [38]) Such kits are easy to use and highly scal-
able but tend to coprecipitate other large complexes and thus not
to be EV-speciﬁc. Immunoafﬁnity methods (e.g., selecting tetra-
spanins) are promising but may be cost prohibitive for large indus-
trial scale preparation. Furthermore, unless the binding antibodies
or other afﬁnity reagents can be easily removed, EV activity may
be impaired by blockage of key molecules. Many of the isolation
methods described in Table 1 can be combined [examples in [39]]
in appropriate workﬂows. Still, these methods are not necessarily
interchangeable with regards to preserving biological properties,
again arguing for reliance on potency assays.
Harmonizing EV production methods across academic labora-
tories (while being careful not to stiﬂe innovation) might have
positive outcomes on its own by enhancing reproducibility. How-
ever, evolving academic production models must also consider
the end goal of translation and production feasibility. As an exam-
ple of larger-scale production model, EVs from 25 to 50 liters of
immortalized neural stem cell-conditioned deﬁned medium have
been isolated using a hollow ﬁber-based tangential ﬂow ﬁltration
(TFF) system [40]. EVs were ﬁrst passed through hollow ﬁbers
with 100 nm pore size, then concentrated and separated from
smaller aggregates using ﬁbers with 300 kDa pore sizes, also allow-
ing buffer exchange [40]. Molecular ﬁngerprinting (capillary gel
electrophoresis, ﬂow cytometry, and Western blotting) indicated
protein composition differences of EVs recovered by standard
stepped ultracentrifugation versus TFF, while TFF had relatively
high batch-to-batch consistency and yield.
Another important issue is whether the method can be per-
formed as a closed system. An alternative open system would
have to be performed in class B or even class A rooms, adding
substantially to cost. EVs, unlike cells, can be sterilized by ﬁltration,
although we recommend endotoxin testing of the end-product to
ensure that microbial contamination has had no inﬂuence. It
remains prudent to select GMP-compliant closed systems to pro-
tect from microbial contamination, avoid regulatory delays, and
possibly circumvent expensive clean rooms.
In choosing an optimal EV isolation method, investigators
should be aware that methods can be changed between Phase I
and Phase II studies. Changes in methodology are even possible
between Phase II and Phase III studies, although it could be a chal-
lenging task to explain such late changes to the satisfaction of the
regulators. Investigators must justify the necessity for the change
and provide adequate evidence of similarity of the therapeutically
active substances used in the different phases. We recommend
that clinical trials be conducted with medicinal products produced
under the same conditions as those to be used for future manu-
facturing processes. For clinical studies, it is critical to have a
reproducible and GMP compliant method with a reproducibility
metric (e.g., molecular ﬁngerprinting).
 Identify optimal cell culture media components and cell cul-
ture conditions, for example, oxygen tension, for generating
Table 1. Established methods of EV puriﬁcation
Method Scalable? Advantages Disadvantages
Magnetic bead isolation Not currently Highly pure end product
Rapid
Costly
Low yield
Depends on knowledge of speciﬁc sur-
face markers
Need to remove Evs from antibodies or
other afﬁnity agents, which may mask
molecules required for target selection
or effect.
Ultraﬁltration Yes Concentrates large volumes Potential losses under high pressure
Differential ultracentrifugation No Commonly used method allowing com-
parison between studies
Can be combined with concentration
methods to produce large quantities
Includes contaminants without addi-
tional isolation steps
Evs may aggregate and lose
functionality
Pellet can be difﬁcult to resuspend
Density gradient
ultracentrifugation
No Commonly used method allowing com-
parison between studies
Some gradient media, for example,
iodixanol, impair EV function less than
others
Among the highest purity products
Some media, for example, sucrose, may
interfere with EV function
Rotor size limits the total volume that
can be processed.
Lengthy: up to several days for this step
alone (e.g., ﬂotation gradients)
High performance liquid
chromatography (size exclusion)
Yes Ideal for large scale Shown to preserve therapeutic activity
Size exclusion chromatography Yes Good separation, removing albumin,
many lipoproteins
Post-column concentration may be
needed
Tangential ﬂow ﬁltration Yes Ideal for industrial manufacture
Precipitation or “salting out” Yes Does not require specialized equipment
Rapid
Polyethylene glycol (PEG) precipitation
has been used to generate clinical grade
Evs
Relatively impure product
PEG may interfere with some down-
stream assays and processes
Abbreviation: EV, extracellular vesicles.
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the EV type and potency most appropriate for the intended
therapeutic use.
 Standardize cell culture conditions for specific cell types. For
example, in the MSC field, no standardized cell culture condi-
tions have been defined, complicating comparison of results
between different labs.
 Optimize and use scalable (ideally closed) purification sys-
tems that preserve EV function.
DEVELOPING TOOLS FOR PRECLINICAL AND CLINICAL STUDIES
Rigorous in vitro and in vivo testing must precede approval of EV-
based therapeutics. There are currently shortcomings in the in
vitro assays used to study EV-based products, from quality control
to MoA. We would therefore like to address opportunities to
bridge the gap between preclinical and early clinical studies, as
presented by three assay types (Table 2), safety testing, and com-
parison with current standards of care.
Fingerprinting Assays
Fingerprinting assays provide quality control and establish batch-
to-batch consistency by examining a narrowly deﬁned set of
molecular surrogate markers of EV therapy that are expected to
be present, absent, or to reach a speciﬁc threshold. Alone or with
consideration of other characteristics such as size range, molecular
markers should be measured at different stages of production and
across batches. Although ﬁngerprints have yet to be standardized
and will likely be speciﬁc to each production process and clinical
indication, their importance should not be underestimated as a
key consideration in the regulatory process. Fingerprints alone
may not prove functionality or identify MoA. Phase I and Phase II
trials, although, will provide ample safety data and may allow cor-
relation with certain effects of batch variation, helping to deﬁne a
reliable molecular ﬁngerprint of the ﬁnal product.
Potency Assays
Like ﬁngerprinting assays, potency assays are recommended to
evaluate batch-to-batch variation and assess conﬁdence in func-
tionality. In vitro potency assays are desirable, as they can be per-
formed more efﬁciently and cheaply than animal studies. Potency
assays establish how well a substance elicits a desired action but
do not necessarily reveal the underlying MoA. For example, T-
cells, NKT cells, and B-cells contribute to antitumor properties of
EVs [41, 42]. A potency assay might determine which cells are acti-
vated by EVs and to what extent, but it may not provide mecha-
nistic information about what signals are being provided to each
cell type. However, the ideal potency assay, anchored in a proven
MoA for a speciﬁc therapeutic use, will provide an accurate pre-
diction of EV potency and will demonstrate whether or not the
same cells and culture conditions consistently yield comparable
EV products.
Potency assays may be required at different stages in the reg-
ulatory process, especially prior to clinical studies. The U.S. Code
of Federal Regulations deﬁnes a potency assay as a quantitative
test of a response to a product at a given dose; ideally, the assay
should be based on the known or intended MoA of the product
[43]. In vitro potency assays do not necessarily predict a therapeu-
tic effect and even less the patient outcome in clinical trials. Rele-
vant national authorities may require potency assays speciﬁcally
tailored to the intended clinical studies, and preclinical studies are
expected to characterize therapeutic activity of an emerging novel
product. Given that EVs are signal carriers, understanding the
MoA and downstream signaling events will guide development of
rigorous in vitro controls and assay readouts. Robust potency
assays will contribute to assessing Proof of Function, or Proof of
Concept, unlikely to come from Phase I trials with an emphasis on
safety. Numerous existing potency assays for pharmaceutical com-
pounds might be adapted to EV-based products, but they are indi-
cation- and application-speciﬁc. EV therapeutics may require
tailored potency assays.
Mechanistic Assays
Mechanistic assays are important not only for future therapeutic
indications, but also to establish positive and negative controls for
potency and ﬁngerprinting assays.While a proven MoA is not nec-
essarily required prior to clinical testing, it is necessary to have a
hypothesis related to the biology of treatment. Clinical studies
enrolling large numbers of participants are a key tool for deter-
mining MoA, correlating EV variation with subject response. For
later trials (Phase III and IV), a deﬁned MoA or a reproducible clini-
cal readout is critical to rigorous study design. Clinicians, who
understand the comorbidities of the patient population, can aid in
identifying the MoA and reﬁning the selection of preclinical ani-
mal models.
Safety Testing
Unlike small molecule pharmaceutical compounds, there are no
deﬁned parameters or assays for safety testing of EV-based thera-
peutics, which are deﬁned as biological medicinal products [4].
Understanding the biodistribution patterns of locally and systemi-
cally administered EVs is important to assessing safety. Novel
labeling systems to track EVs in vivo using ﬂuorescent dyes [44,
45] have been used to show biodistribution to the spleen, liver,
lungs, and kidneys within 30 minutes of injection and to model
half-life and clearance via the hepatic and renal route in mice. An
unanswered question, although, is what proportion of EVs, and
what speciﬁc types of EVs within a preparation exert therapeutic
functions. Possibly, EVs fulﬁlling a cellular “trash disposal” function
have markers that provoke rapid clearance, while signaling EVs
might pass these ﬁlters. Better single EV analysis, say, by advanced
Table 2. Deﬁnition of assay types
Assay type Description
Molecular ﬁngerprinting Identiﬁes the components and composition of a potential drug substance (the molecule/s of interest)
Potency assays Quantiﬁes how well a potential drug substance elicits the desired biologic / therapeutic action or surrogate
activity in vitro and in vivo
Mechanistic assays Identiﬁes how a potential drug substance interacts with the targets in the host organism to elicit the desired
biologic/therapeutic action (mode or mechanism of Action, MoA)
4 Extracellular Vesicle Therapeutics Development
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ﬂow cytometry, is needed to answer this question. Closely related
are the issues of dose and dose response, and more studies into
the latter in particular are encouraged. The argument that expo-
sure to high levels of EVs (e.g., in blood transfusions or other EV-
rich biologicals) demonstrates safety might be weakened if differ-
ent effects are elicited by different subsets of EVs. Finally, EV
source should also be considered in safety testing. While EVs may
be derived from natural or even food substances (milk or plants),
this does not equate with safety for injected use. Safety parame-
ters for established drugs monitor a plethora of systems and
organs and can be used as a model for EVs.
Comparison to Current Standard of Care
In our view, superiority and non-inferiority determinations for EV-
based therapeutics are heavily dependent on dose and route of
administration. Even so, the current standard of care must be con-
sidered when targeting indications for EV-based therapeutics. For
example, anti-cancer therapeutics have a much lower current
standard of care due to the urgent and unmet medical need, sug-
gesting there is room for an effective EV-based therapeutic to sub-
stantially improve patient care. In contrast, congested ﬁelds like
cholesterol-lowering drugs may present a higher burden of proof
for EVs as an improvement over current products. Clinical read-
outs and head-to-head comparison will become necessary as EV-
based drugs move into clinical trials.
Action Items
 Identify and describe molecular fingerprints of EVs for spe-
cific clinical indications.
 Develop reliable, well characterized fingerprinting assays
linked to manufacturing processes.
 Identify and validate the parameters of potency assays for
specific clinical indications.
 Incorporate tailored potency assays to speed development of
EV-specific assays.
 Identify MoA for EVs for specific clinical indications.
 Use MoA data to inform and accelerate development of fin-
gerprinting and potency assays.
 Develop in vivo safety testing parameters for use in clinical
trials.
 Develop noninferiority and superiority testing parameters for
use in clinical trials.
ROLE OF ANIMAL MODELS
Animal models of disease are important to EV therapeutics devel-
opment, not least as we consider rigorous in vivo potency assays.
Therefore, we would like to address some of the issues involved in
selecting and utilizing animal models for EV studies.
Choosing an Animal Model
Appropriate selection of preclinical models will have implications
for understanding how generalizable the effects of an EV-based
therapeutic are in later stage clinical trials. A non-exhaustive list of
frequently used animal models is provided in Table 3. An animal
model must be speciﬁc to the intended use and clinical indication,
some of which (e.g., wound healing and diabetes) have estab-
lished models that might be adapted to EV studies. The model and
species should provide all necessary aspects to mimic human dis-
ease and recovery, whether the disease state is natural or
induced. For example, osteoarthritis requires both immunological
and mechanical aspects that may not be replicated in animals.
Genetic variability and co-morbidities inﬂuence modeling of
human clinical indications. For indications with lifestyle factors
(e.g., weight gain), a heterogeneous animal population might be
beneﬁcial, mirroring comorbidities expected in a clinical study.
However, a homogeneous animal population might mimic
attempts in early-stage clinical trials to limit intersubject variabil-
ity. The economic sustainability of the model and cost per animal
should be weighed against the scientiﬁc beneﬁts. Finally, size mat-
ters: smaller models require fewer EVs.
Use of Human EVs in Animal Models
An outstanding question is whether consensus had been reached
regarding the use of human EVs in animal models. Indeed, this
remains a point of discussion amongst the authors: some espouse
the use of human EVs in animals, while others feel any such use is
dependent on the indication and readouts from the model (espe-
cially immunological readouts). The argument could be made that,
as human EVs are the eventual therapeutic goal, early preclinical
development should focus on human EVs and attempt to establish
low species speciﬁcity. Understanding the MoA in humans and
the animal model(s) will allow an informed decision on whether
human EVs are suitable for cross-species applications.
Control Treatment
After selecting an appropriate model, what is the best control
treatment for EV therapies? Proposals might include saline solu-
tion, sonicated EVs, cell lysate, or EVs from an alternative source
(assumed to be inert). If possible, the control should be chosen
based on the MoA. For example, if RNA cargo were thought to be
the active therapeutic molecule, sonicated EVs might be an appro-
priate control (assuming RNA is exposed and degraded). Sonicated
EVs might not be appropriate if the active therapeutic molecule
were a surface protein, which might persist after sonication.
Limitations of Animal Models
We recognize that each animal model has limitations and that
robust, rigorous in vitro potency assays using human samples
might be sufﬁcient or preferable in some cases. Notably, many
animal models rely on inducing disease in otherwise healthy ani-
mals. Common comorbidity contexts of human patients may not
be replicated; similarly, aged animals may need to be considered
for some studies. Animal models are limited in their capacity for
self-reporting, and the clinical endpoints must therefore be care-
fully deﬁned and reliable to distinguish treatment effects.
Animal Patients Rather Than Animal Models
Clinical work tends to be human-centric, reﬂecting the priorities
of many funding agencies. However, EVs may be tested in clinical
applications in veterinary as well as in human medicine and pro-
vide robust and generalizable evidence of EV function and thera-
peutic efﬁcacy. Companion dogs and cats may serve as good
clinical models for evaluation of MSC-derived EV therapies before
advancing to human clinical trials, because companion animals
are often exposed to similar lifestyle factors (e.g., active vs seden-
tary) as their owners. Although data from animal patients might
be produced under non-GLP (good laboratory practice) conditions,
unlike what would be expected for a preclinical animal study, such
data could still be potentially useful.
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Action Items
 Identify robust animal models specific to EV-related clinical
indications under consideration
 Define rigorous in vivo controls for use in animal models
 Identify and characterize robust endpoints for animal studies
that translate to human clinical trials
 Consider the paradigm of testing EV therapeutics in animal
patients, not models
DEVELOPMENTS IN CLINICAL USE OF EV-BASED THERAPEUTICS
General Overview
There is broad interest in utilizing EVs as therapeutics, whether as
an active compound or delivery system. Searches of clinicaltrials.-
gov over time reveal an expanding number of trials associated
with the search terms “extracellular vesicles,” exosomes,” and
“microvesicles.” Trials utilizing the key words “extracellular
vesicles and exosomes” are scarce by end of the year 2016, but it
is expected that increasing numbers of studies testing EV-based
therapeutics will soon emerge. EVs are being developed primarily
as tools for anti-tumor therapies (with potentially reduced side-
effects compared with existing chemotherapies); vaccination (anti-
gen presentation); regenerative therapies; and drug delivery. Exo-
some and exosome secretome studies (albeit for diagnostic
purposes) are included as primary and secondary endpoints in
numerous clinical trials for almost every indication, reﬂecting
increasing recognition that EVs contribute to pathology in many
different conditions. However, development of EV-related diag-
nostic and prognostic markers has not been systematic to date. In
many cases, a biological function for EVs in the conditions of inter-
est has not been established. Given the high-throughput mecha-
nisms that are used to identify and characterize EVs and their
protein components, this creates the risk of identifying correla-
tions that do not establish causation. Therefore, cautious interpre-
tation is needed, coupled with rigorous basic science studies to
investigate role for EVs in the underlying disease mechanism early
in the process of developing an EV diagnostic, prognostic, or thera-
peutic product.
Anti-Tumor Applications
The application and role of EVs in tumor biology are well estab-
lished [4]. Therapeutic approaches can be broadly categorized as
immunomodulatory or directly anti-tumor. EV origin and composi-
tion can qualitatively change the immune response to EV-
expressed surface antigens. For example, Susanne Gabrielsson’s
group found that repeated injection of soluble antigens rendered
responder cells anergic, whereas EVs loaded with immunostimula-
tory molecules evoked less immune exhaustion and robust natural
killer and CD81 T-cell responses [47]. EV subtypes such as micro-
vesicles and exosomes can provoke different effects, possibly
attributable to uptake or cargo.
Vaccination and Infectious Disease
EVs are released by antigen-presenting cells to modulate immune
responses [48, 49]. They are also released by some microbes dur-
ing infection, delivering virulence factors and eliciting immune
responses [50, 51]. Since EVs are not replication-competent, they
are attractive vaccine candidates. As discussed above, the compo-
sition and origin of EVs used in vaccine design are critical to elicit-
ing a robust immune response. Participants of the ISEV-SOCRATES
Workshop discussed several new developments in this area,
including anti-Plasmodium vaccines [52].
Regenerative Therapies: Examples
Osteoarthritis. Cartilage injuries are major risk factors for osteo-
arthritis (OA). Human MSCs have demonstrated efﬁcacy in carti-
lage repair, but the underlying MoA is not well understood [53].
Wei Seong Toh’s group reported that weekly injections of MSC-
EVs into immunocompetent rats enhanced neocartilage formation
at 6 weeks, along with remodeling and hyaline cartilage and sub-
chondral bone regeneration at 12 weeks [54]. Cartilage regenera-
tion was attributed to EV-mediated enhanced cell survival and
proliferation.
Table 3. Frequently used animal models
Model system Advantages Disadvantages
Small animal models
(rodents, rabbits)
Relatively inexpensive compared with larger animals
Shorter lifespan
Tractable genetics (some)
Immunologically distinct from humans, limits
application (e.g., vaccination)
Findings may require conﬁrmation in other models
Companion animals
(cats, dogs, horses)
Mimic lifestyle diversity based on the owner’s lifestyle
Similar diseases and treatments (vs. human)
Well established veterinary techniques
Not permissible to euthanize the animals
under most circumstances
Costly
Laboratory cats or dogs Carnivores are phylogenomically closer to primates
than to rodents [46]
Controlled environment vs companion animals
Relative genetic homogeny if desired (e.g., dog breeds)
Can be euthanized if necessary
Costly
Farm animals (sheep,
goats, pigs, horses)
Larger size5 ease of product administration
Strong models, for example, pig for cardiac and
transplantation studies
Costly
Limited expertise
For some, young animals preferable
(otherwise too heavy)
Imaging machines designed for humans
needed because of size
Non-human primates
(Not required if
sufﬁcient evidence
can be obtained
from other models)
Most closely related to humans Costly
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Myocardial Infarction. Ischemic heart disease is a leading
cause of death worldwide. It was previously reported that large
paracrine factors mediated protective effects of MSCs in myocar-
dial infarction (MI) [55, 56]. It is now apparent that EVs mediate
these effects both in mouse and pig models. Furthermore, after
cardiosphere-derived cells (CDCs) were shown to produce thera-
peutic regeneration in the infarcted myocardium in rodent and
porcine models and in clinical trials [57], the effects were found to
be mediated largely by CDC-derived EVs [58].
Action Items
 Define and characterize the cargo required for maximal thera-
peutic efficacy, including assessment of proteins, lipids, metab-
olites, and others—not RNA alone—in mediating EV functions.
(It is recognized that these analyses may not be straightfor-
ward or strictly necessary to advance clinical trials.)
 Define the minimum required elements that can be pack-
aged in an EV to direct the immune response to the desired
outcome (e.g., immunostimulatory for vaccination or immu-
nosuppressive for inflammation-mediated applications).
 Define the optimal antigen presentation package to elicit the
desired immune effect for anti-tumor and pathogen responses
(whole protein, peptide loadedMHC, expressed nucleic acids, etc).
CHALLENGES TO FURTHER DEVELOPMENT OF EV THERAPIES
In terms of the regulatory climate and challenges for developing
EV-based therapeutics, several points have become clear:
1. There are multiple components that may be unique to each
preparation/isolation method.
2. The topology of EVs has become somewhat clearer in terms
of what decorates the outside of the membrane versus what
is inside (including nucleic acids that may in some circum-
stances associate with the outside of the EV).
3. Heterogeneity of EVs—or, more precisely, the contents of EV
fractions—has become apparent, and methods are available
and in development to analyze this.
What do these insights mean for developing EV-based thera-
pies? Clearly, the last few years have seen rapid advances in our
knowledge that bring effective EV therapeutics closer to the clinic.
Although questions remain, some of these are best classiﬁed as
challenges for basic molecular science and not impediments to clin-
ical development. EVs seem to exert comparable therapeutic
effects to cell grafts; since they lack nuclei and can be sterilized by
ﬁltration, EVs have some advantages over cells as therapeutic
agents and are likely to be managed differently in the regulatory
environment. For now, it is not known how long EVs exerting the
therapeutic effects remain in the circulation. It has to be considered
that their half life time is much shorter than that of cells, resulting
in the requirement of more repeated applications than for corre-
sponding cellular therapeutics. The stages of clinical development
are shown in Figure 1. Many previously approved products, includ-
ing MSC products, blood products, antibodies, and insulin, may
illustrate different paths through which EVs could be approved.
Regulatory Climate
EVs are perhaps best categorized as “biological medicines.” In
markets including Australia, the EU, and the U.S., biological medi-
cines are regulated as part of the biologics class for pharmaceuti-
cal development. Within that class, multiple possible designations
for EVs have different regulatory burdens (Table 4). EV-based ther-
apeutics have special challenges when it comes to deﬁning the
active ingredient or excipients compared with traditional thera-
peutics, as it is not clear in many cases whether the lipid mem-
brane, the internal content, or a combination thereof is required
for the therapeutic effect. Active research programs are required
to physically characterize the active component of each EV-based
Figure 1. Preclinical studies toward Investigational New Drug ﬁlings.
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therapeutic (considering carefully that the EV itself might be the
active component) and to describe the MoA. This ambiguity may
require speciﬁc regulatory guidance for EV-based therapeutics.
However, as mentioned previously, MoA may be of secondary
importance behind safety and efﬁcacy, and translation may pro-
ceed while the optimal sources and manufacturing processes are
developed. Independent of the MoA-deﬁning molecular compo-
nent, categorization may depend on the genetic manipulation sta-
tus of EV-releasing cells. In principle, EVs could thus be grouped
into three categories: (a) native EVs from nongenetically modiﬁed
cells; (b) EVs from genetically modiﬁed cells, but where the EVs do
not contain transgene products; and (c) EVs containing transgene
products from modiﬁed cells (d). EVs of all three categories can be
considered as biological medicine, however their subcategoriza-
tion may be different. For example, EVs with biologically active
transgene products should be considered advanced therapy
medicinal products (ATMPs); EVs not containing these products
would not fall within this subcategory.
Risk Assessment
Risk assessment is a crucial part of developing a novel therapeutic
product. Novel pharmaceuticals are considered high-risk if they
meet any of three criteria (paraphrasing from [4]): (a) particular
knowledge of the MoA indicates high risk; (b) the nature of the
target is unclear; or (c) the relevance of preclinical animal models
is unclear. While most of these would seem to apply to EVs, there
are equally compelling arguments that EVs are not high-risk. As
previously noted by ISEV [4]: (a) autologous EVs occur naturally in
the body; (b) EVs are passed through blood transfusions and have
not caused major immunological problems; and (c) since there is
substantial evidence that MSCs are safe for autologous or alloge-
neic therapy, it is likely that MSC-derived EVs will also be safe.We
strongly suggest that the body of evidence on safe use of EV-
replete tissues like blood and serum provides a robust basis for
the general safety of EV treatments.
Both short- and long-term risks must be addressed. Short-
term risks include immune responses to multiple injections of allo-
geneic EVs and altered glycosylation patterns on proteins from
immortalized cells. Because some EVs may have potent clinical
effects, overdose should also be considered. Long-term risks
include the potential for EVs from immortalized cells to carry
oncogenic molecules that could epigenetically modify host cells.
Some Workshop participants considered MSC-derived EVs less
risky for allogeneic use than, for example, DC-derived EVs, as the
former contain fewer antigen-presenting molecules, and since
MSCs themselves may inhibit pro-inﬂammatory immune
responses including maturation of B cells [60]. However, based on
current knowledge from animal models, the Workshop partici-
pants considered the risk of sensitization low.
Additional studies may be needed to address the following risk
assessment concerns, which are likely to be raised by regulators:
1. Dose finding and quantification studies. How will the thera-
peutic unit be defined, for example, total RNA content, total
protein content? And what is the relationship to MoA?
2. Safety studies for off-target effects of EV-based therapeutics.
3. Biodistribution and pharmacokinetics profiles.
4. Incidence and severity of allergic reactions.
5. Enrichment of harmful substances in EV-based products
purified from natural sources (e.g., prions from milk).
6. What standards should be implemented to ensure donor
cells are safe?
7. What are the lead molecules in the product?
8. What are the quality assurance processes in place during
manufacturing (including release criteria)?
Manufacturing Processes
An optimal manufacturing process would have the following
attributes:
1. High capacity (albeit of less importance for highly potent
EVs, as determined by dose-response)
2. Closed system with defined, disposable components
3. High yield, reproducible purity
4. Serum-free cell culture conditions
5. Good Manufacturing Practice (GMP) compliance
Regarding GMP compliance, it is important to note that GMP
is meant to document each step in the production process and
Table 4. Possible regulatory designations for EVs
Possible designation for
EV-based therapeutics Description (and see [4)] for more information)
Biological medicinal
products
A biological medicine is a medicine that contains one or more active substances made by or derived from
a biological cell [59]. This classiﬁcation is appropriate for all EV-based products but also for ATMPs (see
below, which are either 1) cell therapy, 2) tissue engineered or 3) gene therapy products.
Advanced therapy
medicinal products (ATMP)
Many EV-based products are not categorized as ATMPs but as biological medicinal products, because EVs
are not tissues or viable cells with a nucleus. The deﬁnitive designation of a particular EV-product as an
ATMP may depend on whether the Evs are produced by a genetically modiﬁed cell and whether the
active substance exerts its therapeutic effects via the modiﬁed gene product (this makes them a gene
therapy product, belonging to the pharmaceutical category of ATMPs).
Active compound Suitable for situations in which the EV has membrane or surface components that are responsible for the
therapeutic effect or is used for targeted delivery of an active compound to a speciﬁc tissue. Knowing
the target of the supposed active molecular structure within the addressed tissue or organ substanti-
ates argumentation of a proposed MoA.
Excipient Suitable for when the EV is used as a necessary delivery vehicle for an active compound or molecule but
is otherwise inert..
Tissues and cells Regulations related to tissues and cells may serve as blueprints for EV-based therapeutic products har-
vested from unmodiﬁed human cells (not passaged or manipulated in any way).
Vesicular paracrine factors (VPFs) Secretome therapeutics likely contain EVs.
Abbreviation: EV, extracellular vesicles.
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ensure consistency in the applied standard operating procedure.
With that understanding in mind, it is up to scientists to develop
the processes and establish the standards that will be deployed to
ensure consistency. At the ISEV-SOCRATES Workshop, Mario
Gimona shared his experience with establishing an accredited
GMP-compliant manufacturing facility for MSC-derived EVs at the
Paracelsus Medical University of Salzburg, Austria. Cells used to
produce EVs were grown in HPL-containing media (with ﬁbrinogen
and platelet EVs removed) rather than serum. Platelet lysate sup-
ports cell expansion while eliminating the xenogeneic components
of bovine serum. EVs are puriﬁed by ultracentrifugation combined
with commercial size-exclusion columns. Empirical optimization of
protocols and rigorous potency testing are required as manufac-
turing processes are scaled, since it must be ensured that changes
in the production process do not change product composition or
efﬁcacy.
Storage and transport conditions must also be optimized. For
example, calcium phosphate crystals in resuspension buffers may
confound particle counting, and EDTA can interact with surface
molecules.Workshop participants noted that the most widely used
buffers are not necessarily appropriate for all applications. Choice
of buffer and other storage and transport parameters should be
based on evidence and may require formal optimization studies.
Later steps in the manufacturing process are the ﬁnal product
release and stability testing over deﬁned time periods. With no
standardized release criteria to date that establish whether an EV
preparation is ready for use and remains stable over time, release
and stability testing will need to be developed for each applica-
tion. Current EV counting methods do not necessarily distinguish
EVs from other particles. However, we consider single EV-based
analysis by ﬂuorescent labeling and advanced ﬂow cytometry to
be an up-and-coming technology to solve this problem. Other
approaches, such as population-based molecular ﬁngerprinting or
quantiﬁcation of speciﬁc cargo (including but not limited to known
active components) may also contribute to release standards.
Maximizing Research Participation
At this stage in the EV development cycle, many researchers per-
ceive challenges to attracting large investments. Funding levels
necessary to move from bench to bedside in Phase III trials are
generally beyond the reach of academic laboratories, emphasizing
the necessity of forming strong collaborative partnerships with
industrial and clinical entities. This situation is expected to change
positively in individual cases and with promising new results. Yet
in the absence of supportive ties, some academic laboratories
may not be well motivated to optimize products for clinical use:
such research may have adverse effects on grant funding or even
be antagonistic to traditionally deﬁned progress, as solving pro-
duction problems is unlikely to result in high-impact publications.
A combination of secured intellectual property and economic fea-
sibility is often required to move from basic to translational sci-
ence. One option to circumvent some of the perceived resource
problems may be for academic laboratories to work toward appli-
cations in rare diseases, where lower regulatory hurdles could
potentially allow more immediate testing. If successful, these
studies could lead to more investment and broader applications.
However, we would like to emphasize that funding on its own
should not be the driving force behind scientiﬁc decisions; our
suggestion is meant only to maximize research participation.
Action Items
1. Develop collaborations of academia, industry, and clinicians.
2. Provide additional evidence that EVs are safe and have
reproducible effects.
3. Identify and define an EV production platform that can be
used for many different applications.
4. Identify target applications (e.g., rare diseases or regenera-
tive medicine) that may use native EVs or otherwise pose
fewer hurdles to testing.
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